ABTI Alpha-Beta Technology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABTI Alpha-Beta Technology

ABTI 0.200

+99,900.0%

Jun 17 12:34 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Eduardo Canto who wrote (387)	8/4/1997 12:31:00 AM
From: Tom D	of 572

One piece of the puzzle. Your statistical analysis is flawless, as far as it goes. But it understates the likelihood of success. Because it is based on only one piece of the puzzle--one of the Phase II studies. The stats don't take into account the other Phase II study, the quality of the studies, the FDA's assessment of the combination of the studies, the fact that the mechanism is well-elucidated, the animal data, etc. See my reply #379 for more details. The best asessment would incorporate all of the information known about betafectin. A rigorous quantitative model for this does not exist. TDD

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next